Octagam (Human Normal Immunoglobulin)

Octagam is an immunoglobulin therapy that modifies immune system activity in several clinical settings.

• Primary immunodeficiency diseases: provides replacement antibodies to reduce infection frequency.
• Chronic inflammatory demyelinating polyneuropathy (CIDP): helps restore nerve function and lessen disability.
• Multifocal motor neuropathy (MMN): improves muscle strength and reduces relapse rates.

• Octagam contains pooled human IgG antibodies that bind to a broad spectrum of antigens, neutralising pathogens and modulating immune cell activity. The preparation also interacts with Fc receptors and complement pathways, leading to down‑regulation of inflammatory responses and restoration of immune homeostasis.

Adverse reactions to Octagam vary with the route of administration and patient factors.

Common Side Effects

• Headache: mild to moderate, often transient.
• Fever or chills: typically occurs during or shortly after infusion.
• Nausea or vomiting: mild gastrointestinal upset.
• Fatigue: general tiredness post‑infusion.
• Muscle aches: transient myalgia.
• Injection site erythema: localized redness.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Acute renal failure: sudden loss of kidney function, especially with high‑dose regimens.
• Thromboembolic events: blood clots that may lead to stroke or pulmonary embolism.
• Hemolytic anemia: destruction of red blood cells.
• Aseptic meningitis: inflammation of the meninges without infection.
• Severe hypotension: marked drop in blood pressure during infusion.

Before initiating Octagam therapy, clinicians should assess patient history and monitor for specific risks.

• Renal function assessment: evaluate baseline creatinine and adjust infusion rate if impaired.
• Thrombotic risk evaluation: consider history of clotting disorders before treatment.
• Pregnancy and lactation counseling: discuss limited data and potential risks.
• Concomitant immunosuppressants: monitor for additive immunosuppression.
• Infusion rate management: start slowly and increase gradually to minimise reactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other medicines that affect immune function or renal clearance.

Major Interactions (Avoid)

• Live vaccines: risk of reduced vaccine efficacy or severe infection.
• High‑dose aspirin or NSAIDs: increased bleeding risk during infusion.

Moderate Interactions (Monitor Closely)

• Nephrotoxic drugs (e.g., aminoglycosides): may worsen renal impairment.
• Anticoagulants (e.g., warfarin): monitor INR and adjust dose as needed.
• Corticosteroids: may augment immunosuppressive effect.
• Diuretics: watch for fluid balance changes during infusion.
• ACE inhibitors: monitor blood pressure for additive hypotensive effect.